NCT00550225 - Succinate Salt Version of GSK961081 for Healthy Volunteers | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 29, 2007

Primary Completion Date

January 8, 2008

Study Completion Date

January 8, 2008

Conditions

Pulmonary Disease, Chronic Obstructive

Interventions

DRUG

GSK961081

GSK961081 edisylate and succinate will be administered as capsules via DISKUS inhaler formulated with lactose as a vehicle to make 12.5 milligrams. GSK961081 succinate will be given in a dose-ascending manner with a starting dose of 300 micrograms. The dose of GSK961081 edisylate is 1500 micrograms.

DRUG

GSK961081 matching placebo

GSK961081 matching placebo formulated with lactose only as a vehicle to 12.5 milligrams will be administered via the DISKUS inhaler.

Trial Locations (1)

NW10 7NS

GSK Investigational Site, London